Show simple item record

dc.contributor.authorJanik, David K.
dc.contributor.authorLindau-Shepard, Barbara
dc.contributor.authorComeau, Anne Marie
dc.contributor.authorPass, Kenneth A.
dc.date2022-08-11T08:10:10.000
dc.date.accessioned2022-08-23T16:58:03Z
dc.date.available2022-08-23T16:58:03Z
dc.date.issued2010-09-28
dc.date.submitted2012-04-09
dc.identifier.citationClin Chem. 2010 Sep;56(9):1460-5. Epub 2010 Jul 21. <a href="http://dx.doi.org/10.1373/clinchem.2010.144329">Link to article on publisher's site</a>
dc.identifier.issn0009-9147 (Linking)
dc.identifier.doi10.1373/clinchem.2010.144329
dc.identifier.pmid20660143
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43284
dc.description.abstractBACKGROUND: Severe combined immunodeficiency (SCID) fulfills many of the requirements for addition to a newborn screening panel. Two newborn screening SCID pilot studies are now underway using the T-cell receptor excision circle (TREC) assay, a molecular technique. Here we describe an immunoassay with CD3 as a marker for T cells and CD45 as a marker for total leukocytes that can be used with the Guthrie specimen. METHODS: The multiplexing capabilities of the Luminex platform were used. Antibody pairs were used to capture and detect CD3 and CD45 from a single 3-mm punch of the Guthrie specimen. The assay for each biomarker was developed separately in identical buffers and then combined to create a multiplex assay. RESULTS: Using calibrators made from known amounts of leukocytes, a detection limit of 0.25 x 10(6) cells/mL for CD3 and 0.125 x 10(6) cells/mL for CD45 was obtained. Affinity tests showed no cross-reactivity between the antibodies to CD3 and CD45. The multiplex assay was validated against 8 coded specimens of known clinical status and linked to results from the TREC assay that had identified them. All were correctly identified by the CD345 assay. CONCLUSIONS: The performance parameters of the CD345 assay met the performance characteristics generally accepted for immunoassays. Our assay classifications of positive specimens concur with previous TREC results. This CD345 assay warrants evaluation as a viable alternative or complement to the TREC assay as a primary screening tool for detecting T-cell immunodeficiencies, including SCID, in Guthrie specimens.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20660143&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220183/pdf/nihms332994.pdf
dc.subjectAntigens, CD3
dc.subjectAntigens, CD45
dc.subjectBlood Specimen Collection
dc.subjectCalibration
dc.subjectFeasibility Studies
dc.subjectHumans
dc.subjectImmunoassay
dc.subjectImmunologic Deficiency Syndromes
dc.subjectInfant, Low Birth Weight
dc.subjectInfant, Newborn
dc.subjectLeukocytes
dc.subjectSevere Combined Immunodeficiency
dc.subjectT-Lymphocytes
dc.subjectGenetics and Genomics
dc.subjectMedical Genetics
dc.subjectPediatrics
dc.titleA multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency disease
dc.typeJournal Article
dc.source.journaltitleClinical chemistry
dc.source.volume56
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_genetics/29
dc.identifier.contextkey2742449
html.description.abstract<p>BACKGROUND: Severe combined immunodeficiency (SCID) fulfills many of the requirements for addition to a newborn screening panel. Two newborn screening SCID pilot studies are now underway using the T-cell receptor excision circle (TREC) assay, a molecular technique. Here we describe an immunoassay with CD3 as a marker for T cells and CD45 as a marker for total leukocytes that can be used with the Guthrie specimen.</p> <p>METHODS: The multiplexing capabilities of the Luminex platform were used. Antibody pairs were used to capture and detect CD3 and CD45 from a single 3-mm punch of the Guthrie specimen. The assay for each biomarker was developed separately in identical buffers and then combined to create a multiplex assay.</p> <p>RESULTS: Using calibrators made from known amounts of leukocytes, a detection limit of 0.25 x 10(6) cells/mL for CD3 and 0.125 x 10(6) cells/mL for CD45 was obtained. Affinity tests showed no cross-reactivity between the antibodies to CD3 and CD45. The multiplex assay was validated against 8 coded specimens of known clinical status and linked to results from the TREC assay that had identified them. All were correctly identified by the CD345 assay.</p> <p>CONCLUSIONS: The performance parameters of the CD345 assay met the performance characteristics generally accepted for immunoassays. Our assay classifications of positive specimens concur with previous TREC results. This CD345 assay warrants evaluation as a viable alternative or complement to the TREC assay as a primary screening tool for detecting T-cell immunodeficiencies, including SCID, in Guthrie specimens.</p>
dc.identifier.submissionpathpeds_genetics/29
dc.contributor.departmentNew England Newborn Screening Program
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages1460-5


This item appears in the following Collection(s)

Show simple item record